Ao Cheng Biology (S3M19), as a highlight of this expo, attracted many guests from home and abroad to visit. Ao Cheng has won wide recognition from the guests with his professional skills and dedicated attitude.

During the exhibition, Ningbo Aocheng will bring its latest product-Placental Growth Factor (PlGF) testing reagents to the exhibition.

Ningbo Aocheng Biotechnology Co., Ltd. approved a new detection product-Placental Growth Factor (PlGF) Detection Kit (Immunofluorescence Method)-obtained the "Early Pregnancy" issued by the International Federation of Obstetrics and Gynecology (FIGO) on June 18, 2019. The “Practical Guidelines for Pre-eclampsia Screening and Prevention” is the strongest recommendation, opening a new era of pre-eclampsia risk assessment and management.

The Aucheer iRaTe PlGF test reagent can help clinicians more reasonably carry out risk stratification and clinical assessment of high-risk factors and pregnant women with suspected preeclampsia, strengthen preeclampsia management, reduce or delay the occurrence and development of preeclampsia, and ensure mother-fetal safety.

The exhibition showcased three major immune testing platforms and testing instruments:Detection techniques include time-resolved fluorescence immunoassay, microfluidic technology and magnetic particle acridinium chemiluminescence.At the same time, the detection mode of the Aucheer PlGF product that was launched this time has changed from single-channel iteration to fully automatic, the detection throughput has been iterated from 20T/hour to 180T/hour, and the detection accuracy CV value has been iterated from CV<15% to CV<5%, which meets the clinical requirements. The different needs of users in medical institutions provide innovative solutions for clinical diagnosis of women's and children's health in an all-round way.

Ningbo Aocheng Biotechnology Co., Ltd. is a high-tech biological enterprise focusing on the early detection, diagnosis, prevention and monitoring of diseases. By providing reliable, fast and convenient in vitro diagnostic products, it can provide accurate test results for diagnosis and treatment.

At present, the company's biomedical team continues to conduct in-depth exploration and prospective research in the field of high-risk diseases for pregnant women such as hypertension.We will be committed to providing professional maternal and child health clinical diagnosis solutions. Promote the standardized management of perinatal preeclampsia in my country, and contribute to the predictive management of preeclampsia in the world.